Lu-177-DOTATATE Peptide Receptor Radionuclide Therapy

被引：2
|
作者：
Abbott, Amanda
Jacene, Heather
机构：
来源：
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | 2018年 / 46卷 / 03期
关键词：
D O I：
10.2967/jnmt.118.217844
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：245 / 246
页数：2
相关论文
共 50 条
  • [41] NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
    Hope, Thomas A.
    Abbott, Amanda
    Colucci, Karen
    Bushnell, David L.
    Gardner, Linda
    Graham, William S.
    Lindsay, Sheila
    Metz, David C.
    Pryma, Daniel A.
    Stabin, Michael G.
    Strosberg, Jonathan R.
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (07) : 937 - 943
  • [42] Safety of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease
    Alsadik, Shahad
    Gnanasegaran, Gopinath
    Chen, Luohai
    Mandair, Dalvinder
    Toumpanakis, Christos
    Caplin, Martyn
    Navalkissoor, Shaunak
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (10) : 1503 - 1508
  • [43] 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy; Gender Differences in Small Intestinal and Pancreatic Neuroendocrine Tumors
    Jahn, U. M. M.
    Jahn, U. M.
    Ilan, E.
    Sandstrom, M.
    Garske-Roman, U.
    Velikyan, I.
    Fross-Baron, K.
    Lubberink, M.
    Sundin, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S61 - S62
  • [44] Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE
    Ilan, Ezgi
    Sandstrom, Mattias
    Wassberg, Cecilia
    Sundin, Anders
    Garske-Roman, Ulrike
    Eriksson, Barbro
    Granberg, Dan
    Lubberink, Mark
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (02) : 177 - 182
  • [45] Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
    Staanum, Peter Frohlich
    Frellsen, Anders Floor
    Olesen, Marie Louise
    Iversen, Peter
    Arveschoug, Anne Kirstine
    EJNMMI PHYSICS, 2021, 8 (01)
  • [46] Comparison of commercial dosimetric software platforms in patients treated with 177Lu-DOTATATE for peptide receptor radionuclide therapy
    Mora-Ramirez, Erick
    Santoro, Lore
    Cassol, Emmanuelle
    Ocampo-Ramos, Juan C.
    Clayton, Naomi
    Kayal, Gunjan
    Chouaf, Soufiane
    Trauchessec, Dorian
    Pouget, Jean-Pierre
    Kotzki, Pierre-Olivier
    Deshayes, Emmanuel
    Bardies, Manuel
    MEDICAL PHYSICS, 2020, 47 (09) : 4602 - 4615
  • [47] A 10-Year Evolution of Patient Dosimetry for Lu-177 Dotatate Peptide Receptor Radionuclide Therapy (PRRT)
    Ross, Erin
    Ram, Lydia
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [48] Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy
    Makis, William
    McCann, Karey
    Riauka, Terence A.
    McEwan, Alexander J. B.
    CLINICAL NUCLEAR MEDICINE, 2015, 40 (11) : 877 - 879
  • [49] 177Lu Dotatate Peptide Receptor Radionuclide Therapy in Chronic Kidney Disease Patients: A Single Center Experience
    Manohar, Sandhya
    Kompotiatis, Panagiotis
    Halfdanarson, Thorvardur R.
    Hobday, Timothy J.
    Thorpe, Matthew
    Johnson, Geoffrey B.
    Kendi, Ayse T.
    Leung, Nelson
    PANCREAS, 2022, 51 (03) : E45 - E46
  • [50] A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors
    Kasi, Pashtoon Murtaza
    Maige, Catherine L.
    Shahjehan, Faisal
    Rodgers, Jessica M.
    Aloszka, Debora L.
    Ritter, Ashton
    Andrus, Margaret L.
    Mcmillan, Jessica M.
    Mody, Kabir
    Sharma, Akash
    Jain, Manoj K.
    FRONTIERS IN ONCOLOGY, 2019, 8
12345